Manmeet Singh Ahluwalia, MD, MBA, FASCO

1995-2000 Maulana Azad Medical College 
 2003-2006 Fairview Hospital, Cleveland, OH 
 2006-2009 Roswell Park Comprehensive Cancer Center 
 2006-2009 Roswell Park Cancer Institute, Buffalo, NY, United States 
 2009-2021 The Cleveland Clinic, Cleveland, OH, United States 
 2009-2021 Cleveland Clinic Foundation, Cleveland, OH, United States 
 2009-2021 Case Western Reserve University, Cleveland Heights, OH, United States 
 2021- Miami Cancer Institute Baptist Health South Florida 
Neuro-Oncology, Brain Metastasis, Glioblastoma, Clinical trials
"Manmeet Ahluwalia"

Manmeet Ahluwalia, MD, MBA, FASCO is the Chief Scientific Officer and the Deputy Director of the Miami Cancer Institute (MCI) at Baptist Health South Florida in Miami, FL, United States ( MCI was the third full member of Memorial Sloan Kettering’s (MSK) Cancer Alliance. MCI is currently the only MSK Cancer Alliance member and the fifth-largest cancer center in the state of Florida. He is also a full professor of translational medicine in Herbert Wertheim College of Medicine at Florida International University.

(Show more)

Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Lee J, Nicosia M, Hong ES, et al. (2023) Sex-biased T cell exhaustion drives differential immune responses in glioblastoma. Cancer Discovery
La Rosa A, Gutierrez AN, Odia Y, et al. (2023) Temporally modulated pulsed proton re-irradiation (TMPPR) for recurrent high-grade gliomas. Neuro-Oncology Advances. 5: vdad074
Tatineni V, O'Shea PJ, Saxena S, et al. (2023) Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010-2019 Retrospective Cohort Study. Cancers. 15
Alban TJ, Grabowski MM, Otvos B, et al. (2023) The SNP rs755622 is associated with immune activation in glioblastoma. Jci Insight
Tatineni V, O'Shea PJ, Ozair A, et al. (2023) First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases. Cancers. 15
Ozair A, Kumar A, Subash NR, et al. (2023) Authorship Diversity in Global Evidence Synthesis in Urology: 1998-2022 Analysis of Cochrane Reviews. Bju International
Grabowski MM, Watson DC, Chung K, et al. (2023) Spatial immunosampling of MRI-defined glioblastoma regions reveals immunologic fingerprint of non-contrast enhancing, infiltrative tumor margins. Medrxiv : the Preprint Server For Health Sciences
Ozair A, Bhat V, Alisch RS, et al. (2023) DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets. Cancers. 15
Dhawan A, Manem VSK, Yeaney G, et al. (2023) EGFR Pathway Expression Persists in Recurrent Glioblastoma Independent of Amplification Status. Cancers. 15
Lehrer EJ, Kowalchuk RO, Gurewitz J, et al. (2023) Concurrent administration of immune checkpoint inhibitors and single fraction stereotactic radiosurgery in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma brain metastases is not associated with an increased risk of radiation necrosis over non-concurrent treatment: An international multicenter study of 657 patients. International Journal of Radiation Oncology, Biology, Physics
See more...